1 / 12

Community-based Clinical Trials: Site Variation and Adoption of Innovation

Allie Buti, MPH Lynn Kunkel , MS, CCRP Holly Fussell, PhD Danielle Eakins, BA Michele Straus, MS, RPh. Community-based Clinical Trials: Site Variation and Adoption of Innovation. American Public Health Association Annual Meeting November 1, 2011 Washington, DC. Dennis McCarty, PhD.

bishop
Download Presentation

Community-based Clinical Trials: Site Variation and Adoption of Innovation

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Allie Buti, MPH Lynn Kunkel, MS, CCRP Holly Fussell, PhD Danielle Eakins, BA Michele Straus, MS, RPh Community-based Clinical Trials: Site Variation and Adoption of Innovation American Public Health Association Annual Meeting November 1, 2011 Washington, DC Dennis McCarty, PhD

  2. Presenter Disclosures Dennis McCarty (1) The following personal financial relationships with commercial interests relevant to this presentation existed during the past 12 months: No relationships to disclose APHA 2011

  3. Overview and Research Question • CTN tests behavioral and pharmaceutical treatments for drug abuse • Multiple sites in each trial • Treatment programs differ: • Client population • Clinicians • Organizational factors • Do organizational and workforce variables influence intention to adopt treatment innovations? APHA 2011

  4. How we measured site differences • Workforce characteristics • Clinician demographics and attitudes • Training and recovery status • Organizational characteristics • Treatment orientation (e.g. 12-step only vs. methadone) • Caseloads and productivity expectations • Culture APHA 2011

  5. What do we know? • Variation in healthcare outcomes – it’s nothing new! • Variation in drug treatment outcomes • Staff attitudes affect treatment (Campbell, et al., 1997) • Site characteristics affect retention (Simpson et al., 1997) • Number of beds affect length of stay (Jonkman et al., 2005) • Variation in CTN Trials • Site by treatment interactions • Distance to outpatient predicted treatment entry (Campbell, et al., 2010) APHA 2011

  6. Site Influences on Treatment Effects (SITE): Goals 1. Assess workforce and organizational variables 2. Examine adoption intentions • Behavioral vs pharmaceutical trials? 3. Explore workforce and organizational influences on patient outcomes* APHA 2011 * Planned future analyses

  7. SITE: How was it done? • Collected data from 5 CTN trials • Results from two trials testing innovations • Web-based CBT • Smoking Cessation Medications • Workforce survey • Demographics • Attitudes, social norms and intentions (Theory of Reasoned Action – Ajzen & Fishbein, 1980) • Data collected before beginning each trial APHA 2011

  8. Two CTN Trials Examined • Web Delivery of Psychosocial Interventions • Web delivered CBT • Significant site differences • Counselor characteristics • race, age, education, recovery status • Perceived social norms, adoption intention • Web-delivered treatment efficacy attitudes • S-CAST (Smoking Cessation and Stimulant Treatment) • Smoking cessation medication: bupropion XL & nicotine inhaler • Significant site differences • Counselor characteristics • race, age, education, recovery status • Attitudes, social norms, adoption intention, • Smoking cessation treatment efficacy attitudes APHA 2011

  9. WEB: Intentions vary by site APHA 2011

  10. S-CAST: Intentions vary by site APHA 2011

  11. SITE: Intention to adopt treatment • Workforce and organizational variables were not significant predictors of intentions to adopt behavioral or pharmacological therapies • Web Delivery of Psychosocial Interventions • Social norms were the strongest predictor of intention • Smoking Cessation and Stimulant Treatment • Social norms were the strongest predictor of intention • Adopt web-based CBT intention (mean = 2.0) • Adopt smoking medications intention (mean = 1.5) (7-point scale scored -3 to +3) APHA 2011

  12. Acknowledgements • An award (U10 DA015815) from the National Institute on Drug Abuse supported the collection and analysis of study data. APHA 2011

More Related